In JAK2-mutant CHIP, treatment with the JAK2 inhibitor ruxolitinib reduced the formation of abnormal neutrophil extracellular traps and deep vein thrombosis [118] as well as the levels of IL-18 in the circulation [112]. This evidence concerns the gene JAK2 and deep vein thrombosis.